Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Upstream Bio, Inc.NASDAQ: UPB
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $1.03M rose 82.7% year over year, ahead of the +44.7% change in trailing-twelve-month revenue. Sequentially, it rose 54.8% from the prior quarter. Over 3 fiscal years it compounded at +33.0% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of $2.59M (-9.1%) for the fiscal year ending Dec 2026, a slowdown from the +20.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.03M+54.8% QoQ
- Last fiscal yearDec 2025
- $2.85M+20.4% YoY
- LTMMar 2026
- $3.32M+44.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +82.7% | -54.0% | -136.7 pp |
| 1 year | +20.4% | -9.1% | -29.5 pp |
| 3-year CAGR | +33.0% | +9.9% | -23.1 pp |
| 5-year CAGR | +76.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 2.85M USD
- Year-over-year change
- +20.4%
- 3-year CAGR
- +33.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.85M | +20.4% |
| FY2024 | 2024-12-31 | 2.37M | -0.4% |
| FY2023 | 2023-12-31 | 2.38M | +96.4% |
| FY2022 | 2022-12-31 | 1.21M | — |
Revenue vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +44.7% is the 4th highest of 8, against a peer median of +23.9%.
- Over three fiscal years its annual growth of +33.0% compares with a peer median of +66.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $596.34M USD | -52.5% | -11.1% | |
| LTM Mar 2026 | $217.17M USD | +396.7% | — | |
| LTM Sep 2026 | $90.49M USD | — | — | |
| LTM Mar 2026 | $71.8M USD | -31.6% | +127.1% | |
| LTM Mar 2026 | $66.09M USD | +45.0% | +9.1% | |
| LTM Jun 2026 | $10.35M USD | +23.9% | +123.2% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $3.32M USD | +44.7% | +33.0% |
| LTM Sep 2026 | $0 USD | +100.0% | — | |
| LTM Sep 2026 | €0 EUR | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| Peer median (excluding UPB) | — | +23.9% | +66.1% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 1.21M | 2.38M | 2.37M | 2.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 1.21M | 2.38M | 2.37M | 2.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 18.66M | 31.8M | 62.97M | 136.81M |
| Selling, General & Admin | 6.46M | 10.7M | 17.17M | 26.41M |
| Operating Expenses | 25.12M | 42.49M | 80.13M | 163.22M |
| Depreciation & Amortization | 7K | 60K | 89K | 188K |
| EBITDA | (23.86M) | (20.48M) | (62.72M) | (143.26M) |
| EBITDA Margin | -1968.7% | -860.4% | -2646.3% | -5019.4% |
| Operating Income | (23.91M) | (40.11M) | (77.76M) | (160.36M) |
| Operating Margin | -1972.7% | -1685.5% | -3281.2% | -5618.8% |
| Interest Income | 205K | 4.17M | 12.12M | 16.93M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 41K | 19.58M | 14.96M | 16.92M |
| Income Before Tax | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Pre-Tax Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (23.87M) | (20.54M) | (62.81M) | (143.44M) |
| Net Margin | -1969.3% | -862.9% | -2650.0% | -5026.0% |
| EPS (Basic) | (0.66) | (1.05) | (1.49) | (2.66) |
| EPS (Diluted) | (0.66) | (1.05) | (1.49) | (2.66) |
| Weighted Avg Shares | 36.32M | 36.32M | 51.34M | 53.85M |
| Weighted Avg Shares (Diluted) | 36.32M | 36.32M | 51.34M | 53.85M |
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.